Explorez le substrat
Search everything we hold — entities, source-backed facts, the conclusions we’re drawing, and the sources behind them. Type a topic, not just a claim. How we source →
22 items across the substrate for “drug discovery”
What we're concluding
8AI Foundation Models Become the New Infrastructure Layer for Drug Discovery
A wave of AI-native platforms and foundation models (NVIDIA BioNeMo, MindWalk's HYFT/ReefIQ, Basecamp's EDEN, Edison's Kosmos, Owkin's OwkinZero, Boltz Lab) is being built out across pharma and biotech R&D, anchored by NVIDIA's hardware partnerships with Thermo Fisher and Lilly and reinforced by MindWalk's move to patent-protect its biological data representation layer. Financial strength at Novo Nordisk (accelerating stock gains, solid Q1 earnings) is coinciding with a strategic pivot away from owning cell therapy manufacturing in-house toward licensing it out to AI-driven specialists like Cellular Intelligence, suggesting capital and R&D focus are rotating toward AI-native platforms rather than traditional biotech infrastructure.
Pharma Hands Drug Discovery to AI Platforms: NVIDIA's BioNeMo Ecosystem, Agentic Research Tools and Data-Architecture IP
Since January 2026, drug discovery has been shifting toward AI-native infrastructure. NVIDIA is the hub: BioNeMo expanded, with lab-in-the-loop partnerships with Lilly and Thermo Fisher. Startups are launching biology foundation models and research agents (Boltz, EDEN, Kosmos, OwkinZero, Bionic Intelligence). Novo Nordisk closed its internal cell therapy unit and licensed its Parkinson's program to the AI-platform company Cellular Intelligence, while its stock rose about 25% over 30 days. MindWalk's July European patent filing on a biological data architecture shows the competition moving to proprietary data representation and IP.
AI Foundation Models Become Biotech's New Infrastructure Layer
A wave of AI-native biological foundation model platforms (NVIDIA BioNeMo, MindWalk's HYFT, Basecamp Research's EDEN, Boltz Lab, Owkin's OwkinZero, Edison Scientific's Kosmos) is emerging as core infrastructure for drug discovery, backed by deep partnerships between chipmakers/AI labs and pharma incumbents (NVIDIA-Thermo Fisher, NVIDIA-Lilly, Tetrascience-Thermo Fisher). Novo Nordisk's strong Q1 earnings and stock rally alongside its decision to shutter its internal cell therapy unit and license a Parkinson's program to AI-native Cellular Intelligence signals a broader pharma pivot from in-house R&D toward outsourcing to specialized AI biotech platforms.
AI Foundation Models Go Bio-Native: Chipmakers, Pharma, and Startups Race to Own the Drug-Discovery Stack
Starting in January 2026, NVIDIA's BioNeMo platform anchored a wave of lab-in-the-loop partnerships with Thermo Fisher and Eli Lilly, catalyzing a broader surge of bio-native AI platform launches (MindWalk's HYFT/ReefIQ, Natera, Boltz Lab, Owkin, Edison Scientific) through mid-2026, with MindWalk now moving to patent its underlying biological data representation. In parallel, established pharma is restructuring around this shift: Novo Nordisk closed its internal cell therapy unit and licensed the program out to the AI-native Cellular Intelligence, even as its stock rallied nearly 25% in 30 days on strong Q1 earnings — signaling investor confidence that AI-driven drug discovery infrastructure, not in-house R&D, is where value is consolidating.
NVIDIA's BioNeMo Ecosystem and AI-Native Biotech Platforms Reshape Pharma R&D
NVIDIA is establishing BioNeMo as core infrastructure for AI-driven drug discovery, cementing partnerships with Thermo Fisher and Lilly for autonomous labs while third parties (Terray Therapeutics, Apheris) ship models on the platform. In parallel, a wave of independent AI foundation-model launches (Boltz Lab, Owkin OwkinZero, Edison Scientific Kosmos, Basecamp Research EDEN, Natera) signals rapid proliferation of AI-native biotech tooling, with Novo Nordisk's pivot to licensing its Parkinson's cell therapy to the AI-driven Cellular Intelligence platform (after shuttering its internal cell therapy unit) exemplifying Big Pharma's shift toward external AI partnerships, all against a backdrop of strong Novo Nordisk earnings and stock performance.
Biotech AI Shifts from Bigger Models to Connected Data and Lab-in-the-Loop Platforms
AI drug discovery is moving from model-scale competition toward infrastructure and data architecture. NVIDIA (BioNeMo, lab partnerships with Lilly and Thermo Fisher) is building the compute and workflow layer. Startups such as MindWalk, with its HYFT patent portfolio and ReefIQ, Cellular Intelligence, Owkin, Boltz, Basecamp Research and Edison Scientific compete on proprietary biological data representation and agentic research tools. Big pharma is reallocating: Novo Nordisk closed its internal cell therapy unit and licensed its Parkinson's program to an AI platform partner while its stock rallied.
Biotech AI Platform Race: Big Pharma, NVIDIA and Specialists Converge on Lab-in-the-Loop Drug Discovery
Between January and July 2026, drug discovery is shifting toward AI-native infrastructure. NVIDIA's BioNeMo expansion and its lab partnerships with Lilly and Thermo Fisher anchor the shift, while startups such as MindWalk, Owkin, Edison Scientific, Boltz, Basecamp Research and Cellular Intelligence compete on data representation, foundation models and autonomous agents. Big pharma is also restructuring: Novo Nordisk closed its internal cell therapy unit and licensed its Parkinson's program to an AI-platform company. Its stock rallied 24.9% over 30 days after Q1 earnings, though the evidence does not show that the AI-related moves caused that rally.
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Faits sourcés
6drug_approvals: 46 novel_drugs (Q4 2025)
drug_approvals: 17 drugssources differ
drug_approvals: 50 novel_drugs (Q4 2024)
Sources we've traced
8AI in Genomics Market Research and Global Forecast Report 2026-2040 - Machine Learning-Driven Drug Discovery and Strategic Tech-Pharma Collaborations Fuel Growth
MindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery
As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
Precision Medicine Analysis Report 2026: A $237.28 Billion Market by 2031 - Strategic Pharma-Big-Tech Alliances Speeding Precision Drug Discovery
Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica
Stellora.AI Advances Quantum Flow to Support Healthcare, Drug Discovery, and Disease Research